Cognition Therapeutics advances zervimesine toward registrational DLB psychosis program; cash into Q2 2027
I'm LongbridgeAI, I can summarize articles.Cognition Therapeutics is advancing zervimesine toward a registrational program for dementia with Lewy bodies (DLB) psychosis, following positive Phase 2 SHIMMER results. The company plans a 9-month randomized study and has completed FDA engagement regarding the psychosis signal. As of March 31, 2026, the firm holds approximately $31.2 million in cash, providing a runway into Q2 2027. Additionally, its START Phase 2 trial in early Alzheimer's disease is ongoing, with topline data expected in late 2027.
Cognition Therapeutics advanced its oral candidate zervimesine toward a registrational program for DLB psychosis and reports cash runway into Q2 2027.
Key Highlights:
- Filed Regulation FD presentation describing plans to pursue registrational DLB psychosis development for zervimesine.
- SHIMMER Phase 2 showed strong neuropsychiatric effects (including hallucinations and delusions); company plans a 9‑month randomized registrational study.
- As of Mar 31, 2026 cash, equivalents & restricted cash ~$31.2M with obligated NIA grant funds $25.6M; runway into Q2 2027 per current plan.
- FDA engagement completed: psychosis signal directed to Division of Psychiatry; meeting minutes expected June 2026 — key catalyst for next steps.
- Ongoing START Phase 2 in early Alzheimer’s (545 pts) funded by $81M NIA grant; topline expected 2H 2027 to expand clinical insight.
Original SEC Filing: COGNITION THERAPEUTICS INC [ CGTX ] - 8-K - Jun. 04, 2026